

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

PRO PHARMACEUTICALS INC  
Form 8-K  
May 18, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of  
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2005

PRO-PHARMACEUTICALS, INC.

-----  
(Exact name of registrant as specified in its charter)

Nevada	000-32877	04-3562325
----- (State or other jurisdiction of incorporation)	----- (Commission File Number)	----- (IRS Employer Identification No.)
189 Wells Avenue, Newton, Massachusetts (Address of principal executive offices)		02459 (Zip Code)

Registrant's telephone number, including area code: (617) 559-0033

Not Applicable

-----  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On May 9, 2005, Pro-Pharmaceuticals, Inc. issued a news release announcing the dosing of patients in a Phase II trial of its DAVANAT(R)/5-FU product has commenced. The Phase II clinical trial is in metastatic colorectal cancer

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

patients who have disease progression after receiving standard chemotherapeutic regimens. A copy of Pro-Pharmaceutical's news release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

99.1 News release of Pro-Pharmaceuticals, Inc. dated May 9, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

By: /s/ Carl Lueders

-----  
Carl Lueders  
Chief Financial Officer

Date: May 18, 2005